Progyny, Inc. Common Stock (PGNY) is a publicly traded Healthcare sector company. As of May 21, 2026, PGNY trades at $25.61 with a market cap of $1.88B and a P/E ratio of 37.40. PGNY moved +4.35% today. Year to date, PGNY is -3.83%; over the trailing twelve months it is +17.24%. Its 52-week range spans $13.39 to $28.75. Analyst consensus is strong buy with an average price target of $27.75. Rallies surfaces PGNY's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Barclays Raises Progyny Price Target to $27 After Q1 EPS Beat: Barclays raised its price target for Progyny to $27.00 from $23.00 and maintained an Overweight rating after the company reported Q1 EPS of $0.50, beating the $0.44 estimate. Progyny delivered record Q1 revenue of $328.5 million, repurchased 8.8 million shares since last November, and holds a $1.82 billion market capitalization.
| Metric | Value |
|---|---|
| Price | $25.61 |
| Market Cap | $1.88B |
| P/E Ratio | 37.40 |
| EPS | $0.68 |
| Dividend Yield | 0.00% |
| 52-Week High | $28.75 |
| 52-Week Low | $13.39 |
| Volume | 1.78M |
| Avg Volume | 0 |
| Revenue (TTM) | $1.29B |
| Net Income | $58.52M |
| Gross Margin | 23.63% |
9 analysts cover PGNY: 0 strong buy, 7 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $27.75.